Trends and associated characteristics for Chagas disease among women of reproductive age in the United States, 2002 to 2017.

Chagas disease Ethnic/racial disparities HCUP Neglected disease Reproductive health United States

Journal

Parasite epidemiology and control
ISSN: 2405-6731
Titre abrégé: Parasite Epidemiol Control
Pays: Netherlands
ID NLM: 101687137

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 26 03 2020
revised: 14 07 2020
accepted: 15 07 2020
entrez: 4 8 2020
pubmed: 4 8 2020
medline: 4 8 2020
Statut: epublish

Résumé

American trypanosomiasis, commonly referred to as Chagas disease, is caused by a single cell protozoan known as We analyzed admissions data including socio-demographic and hospital characteristics for inpatient hospitalization for women of reproductive age (15-49 years) in the US from 2002 through 2017. We employed Joinpoint regression analysis to determine trends in the prevalence of Chagas disease over this period. A total of 487 hospitalizations of Chagas disease were identified, corresponding to 3.7 per million hospitalizations over the study period. The rate statistically increased from 1.6 per million in 2002 to 7.6 per million hospitalizations in 2017. Chagas was most prevalent among older women, Hispanics and those in the highest zip income bracket. The in-hospital mortality rate was about 10 times greater among women with Chagas compared to those without the condition (3.1% versus 0.3%), and the condition tended to be clustered in women treated at large, urban teaching hospitals in the Northeastern region of the US. Chagas disease diagnosis appears to be increasing among hospitalized women of reproductive age in the US with a 10-fold elevated risk of mortality.

Sections du résumé

BACKGROUND BACKGROUND
American trypanosomiasis, commonly referred to as Chagas disease, is caused by a single cell protozoan known as
METHODS METHODS
We analyzed admissions data including socio-demographic and hospital characteristics for inpatient hospitalization for women of reproductive age (15-49 years) in the US from 2002 through 2017. We employed Joinpoint regression analysis to determine trends in the prevalence of Chagas disease over this period.
RESULTS RESULTS
A total of 487 hospitalizations of Chagas disease were identified, corresponding to 3.7 per million hospitalizations over the study period. The rate statistically increased from 1.6 per million in 2002 to 7.6 per million hospitalizations in 2017. Chagas was most prevalent among older women, Hispanics and those in the highest zip income bracket. The in-hospital mortality rate was about 10 times greater among women with Chagas compared to those without the condition (3.1% versus 0.3%), and the condition tended to be clustered in women treated at large, urban teaching hospitals in the Northeastern region of the US.
CONCLUSION CONCLUSIONS
Chagas disease diagnosis appears to be increasing among hospitalized women of reproductive age in the US with a 10-fold elevated risk of mortality.

Identifiants

pubmed: 32743081
doi: 10.1016/j.parepi.2020.e00167
pii: S2405-6731(20)30036-2
pii: e00167
pmc: PMC7388767
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e00167

Informations de copyright

© 2020 The Authors. Published by Elsevier Ltd on behalf of World Federation of Parasitologists.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Lancet. 2018 Jan 6;391(10115):82-94
pubmed: 28673423
Mem Inst Oswaldo Cruz. 2013 Dec;108(8):962-7
pubmed: 24402148
PLoS Negl Trop Dis. 2011 Apr 26;5(4):e1135
pubmed: 21572511
MMWR Morb Mortal Wkly Rep. 2018 Jul 06;67(26):738-741
pubmed: 29975678
Transfusion. 2012 Sep;52(9):1901-11
pubmed: 22339233
PLoS Negl Trop Dis. 2016 Nov 7;10(11):e0005033
pubmed: 27820837
Mem Inst Oswaldo Cruz. 2014 Nov;109(7):856-62
pubmed: 25410988
Clin Infect Dis. 2009 Sep 1;49(5):e52-4
pubmed: 19640226
Acta Trop. 2016 Apr;156:68-78
pubmed: 26777312

Auteurs

Chioma Ikedionwu (C)

Center of Excellence in Health Equity, Training, and Research, Baylor College of Medicine, Houston, TX, USA.

Deepa Dongarwar (D)

Center of Excellence in Health Equity, Training, and Research, Baylor College of Medicine, Houston, TX, USA.

Manvir Kaur (M)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Lisa Nunez (L)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Annabella Awazi (A)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Jere' Mallet (J)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

KaShena Kennedy (K)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Michelle Cano (M)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Chinwe Dike (C)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Jessica Okwudi (J)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Justice Stewart (J)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

David Igwegbe (D)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Flora G Estes (FG)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Kiara K Spooner (KK)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.

Jason L Salemi (JL)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.

Hamisu M Salihu (HM)

Center of Excellence in Health Equity, Training, and Research, Baylor College of Medicine, Houston, TX, USA.
Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.

Omonike A Olaleye (OA)

College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.

Classifications MeSH